Treatment Outcome of FOLFOX Versus Carboplatin–Paclitaxel as First Line Therapy for Advanced Squamous Cell Carcinoma of the Esophagus At TASH, Addis Ababa Ethiopia: A Comparative Retrospective Study.
| dc.contributor.advisor | Mathewos Assefa | |
| dc.contributor.advisor | Sonia Worku | |
| dc.contributor.author | Ikram Musa | |
| dc.date.accessioned | 2026-06-18T14:58:24Z | |
| dc.date.available | 2026-06-18T14:58:24Z | |
| dc.date.issued | 2025-12-01 | |
| dc.description.abstract | Background: Esophageal Squamous Cell Carcinoma (ESCC) Is One of the Most Common Sub-Types of Esophageal Cancer in Sub-Saharan Africa. The Majority of Patients Present with Unresectable or Metastatic Disease Usually Accompanied with Malnourishment and Poor General Condition. FOLFOX And Carboplatin/Paclitaxel Are Used as First-Line Therapy for Advanced Diseases. Howev Er, There Is No Data on the Comparative Effectiveness and Safety of These Regimens Africa. Objective: To Compare the Treatment Outcome of FOLFOX Versus Carboplatin–Paclitaxel as First-Line Therapy for Advanced Squamous Cell Carcinoma of the Esophagus. Methods: Patients With Stage IV Esophageal Squamous Cell Carcinoma Treated Between Febru Ary 2023- February 2025 Who Met the Inclusion and Exclusion Criteria Who Were Included. Data Was Analyzed Using Descriptive Statistics, Kaplan-Meier Curves, Log-Rank Tests, And Multivariable Analysis to Compare Outcomes Between Treatment Groups. Results: A Total Of 55 Patients with Stage IV Esophageal Squamous Cell Carcinoma Were Include Ed, With A Median Age Of 56 Years. Thirty Patients (54.5%) Received Carboplatin–Paclitaxel And 25 (45.5%) Received FOLFOX. The Overall Response Rate Was Higher with Carboplatin–Paclitaxel Than FOLFOX At Both Mid-Cycle (67.9% Vs. 47.8%) And End-Cycle Assessments, With Greater Mean Tumor Reduction (66.3% Vs. 49.4%, P = 0.038). The Median Overall Survival (OS) For the Entire Cohort Was 9 Months (95% CI: 7.2–10.3), With A 1-Year OS Of 45%. Median OS Was 9.0 Months for Carboplatin–Paclitaxel And 8.0 Months For FOLFOX, With No Significant Difference Between Regimens (P = 0.286). Treatment-Related Toxicities Occurred In 52.7% Of Patients, Pre-Dominantly Hematologic. Grade 3–4 Neutropenia Was Observed In 10.9%. Severe Hematologic Toxicities Were More Common with Carboplatin–Paclitaxel (16.7% Vs. 4.0%), Whereas Peripheral Neuropathy Occurred More Frequently with FOLFOX (8.0% Vs. 0%). | |
| dc.identifier.uri | https://etd.aau.edu.et/handle/123456789/8217 | |
| dc.language.iso | en | |
| dc.publisher | Addis Ababa University | |
| dc.subject | Esophageal Squamous Cell Carcinoma | |
| dc.subject | Response Rate | |
| dc.subject | Treatment Related Toxicity | |
| dc.subject | Folfox | |
| dc.subject | Carboplatin-Paclitaxel | |
| dc.subject | Survival | |
| dc.title | Treatment Outcome of FOLFOX Versus Carboplatin–Paclitaxel as First Line Therapy for Advanced Squamous Cell Carcinoma of the Esophagus At TASH, Addis Ababa Ethiopia: A Comparative Retrospective Study. | |
| dc.type | Thesis |